Skip to main content Accessibility help
×
Home
Addiction Neuroethics
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 7
  • Export citation
  • Recommend to librarian
  • Buy the print book

Book description

Addiction is a significant health and social problem and one of the largest preventable causes of disease globally. Neuroscience promises to revolutionise our ability to treat addiction, lead to recognition of addiction as a 'real' disorder in need of medical treatment and thereby reduce stigma and discrimination. However, neuroscience raises numerous social and ethical challenges:• If addicted individuals are suffering from a brain disease that drives them to drug use, should we mandate treatment?• Does addiction impair an individual's ability to consent to research or treatment?• How will neuroscience affect social policies towards drug use?Addiction Neuroethics addresses these challenges by examining ethical implications of emerging neurobiological treatments, including: novel psychopharmacology, neurosurgery, drug vaccines to prevent relapse, and genetic screening to identify individuals who are vulnerable to addiction. Essential reading for academics, clinicians, researchers and policy-makers in the fields of addiction, mental health and public policy.

Refine List

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Send to Kindle
  • Send to Dropbox
  • Send to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
×

Contents


Page 1 of 2



Page 1 of 2


Bibliography

Abelson, J. L., Curtis, G. C., Sagher, O., et al. (2005). Deep brain stimulation for refractory obsessive-compulsive disorder. Biological Psychiatry, 57, 510–516.
Abler, B., Walter, H. and Erk, S. (2005). Neural correlates of frustration. Neuroreport, 16, 669–672.
Academy of Medical Sciences. (2008). Brain Science, Addiction and Drugs. London: Academy of Medical Sciences.
Addolorato, G., Leggio, L., Ferrulli, A., et al. (2007). Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet, 370, 1915–1922.
Adhikari, B., Kahende, J., Malarcher, A., et al. (2008). Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. Morbidity and Mortality Weekly Report, 57, 1226–1228.
Adler, M. W. (1995). Human subject issues in drug-abuse research. Drug and Alcohol Dependence, 37, 167–175.
Agid, Y., Schupbach, M., Gargiulo, M., et al. (2006). Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so?Journal of Neural Transmission. Supplementum, 70, 409–414.
Ahmed, S. H. (2010). Validation crisis in animal models of drug addiction: beyond non-disordered drug use toward drug addiction. Neuroscience & Biobehavioral Reviews, 35, 172–184.
AIHW. (2008). National Drug Strategy Household Survey: Detailed Findings. Canberra: Australian Institute of Health and Welfare.
Ainslie, G. (2000). A research-based theory of addictive motivation. Law and Philosophy: An International Journal for Jurisprudence and Legal Philosophy, 19, 77–115.
Ainslie, G. (2001). Breakdown of Will. New York: Cambridge University Press.
Akil, H., Brenner, S., Kandel, E., et al. (2010). Medicine. The future of psychiatric research: genomes and neural circuits. Science, 327, 1580–1581.
Alexander, B. K., Beyerstein, B. L., Hadaway, P. F., et al. (1981). Effect of early and later colony housing on oral ingestion of morphine in rats. Pharmacology, Biochemistry and Behavior, 15, 571–576.
Alexander, B. K., Coambs, R. B. and Hadaway, P. F. (1978). The effect of housing and gender on morphine self-administration in rats. Psychopharmacology, 58, 175–179.
Ali, R., Christie, P. and Lenton, S. (1999). The Social Impacts of the Cannabis Expiation Notice Scheme in South Australia. Summary Report Presented to the Ministerial Council on Drug Strategy. Canberra: Commonwealth Department of Health and Aged Care.
Alonso-Zaldivar, R. (2008). Senate passes genetic discrimination bill. Los Angeles Times. Available at: http://articles.latimes.com/2008/apr/25/nation/na-genes25 (Accessed 25 January, 2009.)
Alper, J. S. and Beckwith, J. (1993). Genetic fatalism and social-policy: the implications of behavior genetics research. Yale Journal of Biology and Medicine, 66, 511–524.
Amato, L., Davoli, M., Perucci, C. A., et al. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment, 28, 321–329.
Ambermoon, P., Carter, A., Hall, W., et al. (2011). Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction, 106, 283–293.
American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders – Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
Anand, S. and Hotson, J. (2002). Transcranial magnetic stimulation: neurophysiological applications and safety. Brain and Cognition, 50, 366–386.
ANCD. (2005). Key Principles for the Reporting of Drug Issues. Canberra: Australian National Council on Drugs.
ANCD. (2007). The Australian Alcohol and Other Drugs Charter. Canberra: Australian National Council on Drugs.
Anderer, S. J. (1992). Introduction to the symposium: integrating legal and psychological perspectives on the right to personal autonomy. Villanova Law Review, 37, 1536–1568.
Anderlik, M. R. and Rothstein, M. A. (2001). Privacy and confidentiality of genetic information: what rules for the new science?Annual Review of Genomics and Human Genetics, 2, 401–433.
Andlin-Sobocki, P. and Rehm, J. (2005). Cost of addiction in Europe. European Journal of Neurology, 12 Suppl 1, 28–33.
Angermeyer, M. C. and Matschinger, H. (2005). Have there been any changes in the public's attitudes towards psychiatric treatment? Results from representative population surveys in Germany in the years 1990 and 2001. Acta Psychiatrica Scandinavica, 111, 68–73.
Anon. (2005). How volunteering for an MRI scan changed my life. Nature, 434, 17.
Anthony, J. C., Warner, L. and Kessler, R. C. (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology, 2, 244–268.
Anton, R. F., Oroszi, G., O'Malley, S., et al. (2008). An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry, 65, 135–144.
Aos, S., Miller, M., Drake, E., et al. (2006). Evidence-Based Public Policy Options to Reduce Future Prison Construction, Criminal Justice Costs, and Crime Rates. Olympia, WA: Washington State Institute for Public Policy.
Appelbaum, P. S. (2010). Law and psychiatry: genetic discrimination in mental disorders: the impact of the genetic information nondiscrimination act. Psychiatric Services, 61, 338–340.
Appelbaum, P. S., Roth, L. H., Lidz, C. W., et al. (1987). False hopes and best data: consent to research and the therapeutic misconception. Hastings Center Report, 17, 20–24.
Ardouin, C., Voon, V., Worbe, Y., et al. (2006). Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Movement Disorders, 21, 1941–1946.
Aronowitz, D. (1967). Civil commitment of narcotics addicts. Columbia Law Review, 67, 405–429.
Ascher, J. A., Cole, J. O. and Colin, J. N. (1995). Bupropion: a review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry, 56, 395–401.
Ashcroft, R. (2005). Making sense of dignity. Journal of Medical Ethics, 31, 679–682.
Ashcroft, R., Campbell, A. and Capps, B. (2007). Ethical aspects of developments in neuroscience and drug addiction. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 439–466). London: Academic Press.
Ashcroft, R. and Franey, C. (2004). Further ethical and social issues in using a cocaine vaccine: response to Hall and Carter. Journal of Medical Ethics, 30, 341–343.
Audrain, J., Boyd, N. R., Roth, J., et al. (1997). Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial. Addictive Behaviors, 22, 741–751.
Australian Press Council. (2001). Reporting guidelines: drugs and drug addiction. General Press Release No. 246. Available at: http://www.presscouncil.org.au/pcsite/activities/guides/gpr246_2.html (Accessed 6 July 2009.)
Avery, L. and Campbell, S. (1941). Shock therapy as an aid to the withdrawal of morphine in addiction. Disorders of the Nervous System, 2, 333–335.
Babor, T., Caetano, R., Casswell, S., et al. (2003). Alcohol: No Ordinary Commodity. Research and Public Policy. Oxford: Oxford University Press.
Babor, T., Miller, P. and Edwards, G. (2010). Vested interests, addiction research and public policy. Addiction, 105, 4–5.
Backlar, P. (1996). Genes and behavior: will genetic information change the way we see ourselves?Community Mental Health Journal, 32, 205–209.
Badenoch, J. (2002). A death following ultra-rapid opiate detoxification: the General Medical Council adjudicates on a commercialized detoxification. Addiction, 97, 475–477.
Balasubramaniam, V., Kanaka, T. S. and Ramanujam, P. B. (1973). Stereotaxic cingulumotomy for drug addiction. Neurology India, 21, 63–66.
Baldwin, R. (1979). Proposals for the Drug and Alcohol Court Assessment Programme. Sydney: NSW Drug and Alcohol Authority Internal Paper.
Baler, R. D. and Volkow, N. D. (2006). Drug addiction: the neurobiology of disrupted self-control. Trends in Molecular Medicine, 12, 559–566.
Balfour, D. J. (2004). The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine and Tobacco Research, 6, 899–912.
Ball, A. L. (2007). HIV, injecting drug use and harm reduction: a public health response. Addiction, 102, 684–690.
Ball, D. (2008). Addiction science and its genetics. Addiction, 103, 360–367.
Ball, D. and Collier, D. (2002). Substance misuse. In P. McGuffin, M. J. Owen and I. I. Gottesman (Eds.), Psychiatric Genetics and Genomics (pp. 267–302). Oxford: Oxford University Press.
Ball, D., Pembrey, M. and Stevens, D. (2007). Genomics. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 89–132). London: Academic Press.
Ballard, P. and Radley, A. (2009). Give it up for baby: a smoking cessation intervention for pregnant women in Scotland. Cases in Public Health Communication & Marketing, 3, 147–160.
Ballon, B. C. and Skinner, W. (2008). Attitude is a little thing that makes a big difference: reflection techniques for addiction psychiatry training. Academic Psychiatry, 32, 218–224.
Baltuch, G. H. and Stern, M. B. (2007). Deep Brain Stimulation for Parkinson's Disease. New York: Informa Healthcare.
Barclay, G. A. (1964). The Keeley League. Journal of the Illinois State Historical Society (1908–1984), 57, 341–365.
Barnes, R. E. (2000). Reefer madness: legal and moral issues surrounding the medical prescription of marijuana. Bioethics, 14, 16–41.
Barrett, D. and Nowak, M. (2009). The United Nations and drug policy: towards a human rights-based approach. In A. Constantinides and N. Zaikos (Eds.), The Diversity of International Law: Essays in Honour of Professor Kalliopi K. Koufa (pp. 449–477). Boston: Martinus Nijhoff Publishers.
Baudelaire, C. (2002). On Wine and Hashish. London: Hesperus.
Bauer, R., Pohl, S., Klosterkotter, J., et al. (2008). [Deep brain stimulation in the context of addiction – a literature-based systematic evaluation]. Fortschritte der Neurologie-Psychiatrie, 76, 396–401.
Baumeister, R. F. (2003). Ego depletion and self-regulation failure: a resource model of self-control. Alcoholism, Clinical and Experimental Research, 27, 281–284.
BBC News. (2004). ‘DNA test’ to help smokers quit. BBC News. Available at: http://news.bbc.co.uk/2/hi/health/4061137.stm (Accessed 25 January 2007.)
BBC News. (2007). Brain's ‘addiction centre’ found. BBC News. Available at: http://news.bbc.co.uk/2/hi/health/6298557.stm (Accessed 2 August 2007.)
Beauchamp, T. L. and Childress, J. F. (2001). Principles of Biomedical Ethics. New York: Oxford University Press.
Bechara, A. (2001). Neurobiology of decision-making: risk and reward. Seminars in Clinical Neuropsychiatry, 6, 205–216.
Bechara, A. (2005). Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nature Neuroscience, 8, 1458–1463.
Bechara, A., Dolan, S., Denburg, N., et al. (2001). Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia, 39, 376–389.
Becker, A., Grecksch, G., Brodemann, R., et al. (2000). Morphine self-administration in mu-opioid receptor-deficient mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 361, 584–589.
Begg, S., Vos, T., Barker, B., et al. (2007). The Burden of Disease and Injury in Australia 2003. Canberra: Australian Institute of Health and Welfare.
Belenko, S. (2002). The challenges of conducting research in drug treatment court settings. Substance Use & Misuse, 37, 1635–1664.
Bell, E., Maxwell, B., Sadikot, A., et al. (2010). Healthcare providers' perspectives and approaches. Journal of Clinical Ethics, 21, 113–125.
Bell, J., Chan, J. and Kuk, A. (1995). Investigating the effect of treatment philosophy on outcome of methadone maintenance. Addiction, 90, 823–830.
Bell, J., Hall, W. and Byth, K. (1992). Changes in criminal activity after entering methadone maintenance. British Journal of Addiction, 87, 251–258.
Benabid, A. L., Pollak, P., Seigneuret, E., et al. (1993). Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochirurgica. Supplementum, 58, 39–44.
Bennett, P. and Smith, S. (2007). Genetics, insurance and participation: how a citizen's jury reached its verdict. Social Science and Medicine, 64, 2487–2498.
Bentham, J. (1988). The Principles of Morals and Legislation. Buffalo, NY: Prometheus Books.
Berke, J. D. (2003). Learning and memory mechanisms involved in compulsive drug use and relapse. Methods in Molecular Medicine, 79, 75–101.
Berke, J. D. and Hyman, S. E. (2000). Addiction, dopamine, and the molecular mechanisms of memory. Neuron, 25, 515–532.
Berridge, K. C. (2007). The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology, 191, 391–431.
Berridge, K. C. and Robinson, T. E. (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?Brain Research Reviews, 28, 309–369.
Bersoff, D. N. (1992). Autonomy for vulnerable populations: the Supreme Court's reckless disregard for self-determination and social science. Villanova Law Review, 37, 1569–1605.
Bigelow, G. E., Brooner, R., Walsh, S., et al. (1994). Community outcomes following research exposure to cocaine or opioids. In: L. Harris. (Ed), Problems of Drug Dependence: Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence (Volume 2), 354. Baltimore, MD: National Institute on Drug Abuse.
Billings, P. R., Kohn, M. A., Decuevas, M., et al. (1992). Discrimination as a consequence of genetic testing. American Journal of Human Genetics, 50, 476–482.
Bjorklund, A. and Dunnett, S. B. (2007). Fifty years of dopamine research. Trends in Neurosciences, 30, 185–187.
Blakemore, C. (2002). From the “public understanding of science” to scientists' understanding of the public. In S. J. Marcus (Ed.), Neuroethics: Mapping the Field (pp. 211–221). New York: Dana Press.
Boeijinga, P. H., Parot, P., Soufflet, L., et al. (2004). Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology, 50, 71–77.
Bonese, K. F., Wainer, B. H., Fitch, F. W., et al. (1974). Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature, 252, 708–710.
Bonson, K. R., Grant, S. J., Contoreggi, C. S., et al. (2002). Neural systems and cue-induced cocaine craving. Neuropsychopharmacology, 26, 376–386.
Brandt, A. M. (2007). The Cigarette Century. Atlanta, GA: Basic Books.
Brebner, K., Ahn, S. and Phillips, A. G. (2005). Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates. Psychopharmacology, 177, 409–417.
Brodie, J. D., Figueroa, E., Laska, E. M., et al. (2005). Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse, 55, 122–125.
Brody, B. A. (1998). The Ethics of Biomedical Research: An International Perspective. New York: Oxford University Press.
Brody, B. A. (2003). Taking Issue: Pluralism and Casuistry in Bioethics. Washington, DC: Georgetown University Press.
Brown, S. M., Manuck, S. B., Flory, J. D., et al. (2006). Neural basis of individual differences in impulsivity: contributions of corticolimbic circuits for behavioral arousal and control. Emotion, 6, 239–245.
Bruce, R. D. and Schleifer, R. A. (2008). Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention. International Journal of Drug Policy, 19, 17–23.
Bruijnzeel, A. W. and Gold, M. S. (2005). The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Research. Brain Research Reviews, 49, 505–528.
Bush, G., Whalen, P. J., Rosen, B. R., et al. (1998). The Counting Stroop: an interference task specialized for functional neuroimaging – validation study with functional MRI. Human Brain Mapping, 6, 270–282.
Cairns, R., Maddock, C., Buchanan, A., et al. (2005). Reliability of mental capacity assessments in psychiatric in-patients. British Journal of Psychiatry, 187, 372–378.
Calabresi, P., Picconi, B., Tozzi, A., et al. (2007). Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neurosciences, 30, 211–219.
Callahan, D. (2003). Principlism and communitarianism. Journal of Medical Ethics, 29, 287–291.
Campbell, D. E. and Fleischman, A. R. (1992). Ethical challenges in medical care for the pregnant substance abuser. Clinical Obstetrics and Gynecology, 35, 803–812.
Campbell, N. C. (2007). Discovering Addiction: The Science and Politics of Substance Abuse Research. Ann Arbor: University of Michigan Press.
Canli, T. and Amin, Z. (2002). Neuroimaging of emotion and personality: scientific evidence and ethical considerations. Brain and Cognition, 50, 414–431.
Cantin, L., Lenoir, M., Augier, E., et al. (2010). Cocaine is low on the value ladder of rats: possible evidence for resilience to addiction. PLoS ONE, 5, e11592.
Caplan, A. (2002). No brainer: can we cope with the ethical ramifications of new knowledge of the human brain. In S. Marcus (Ed.), Neuroethics: Mapping the Field (pp. 95–131). San Francisco: The Dana Press.
Caplan, A. (2006). Ethical issues surrounding forced, mandated, or coerced treatment. Journal of Substance Abuse Treatment, 31, 117–120.
Caplan, A. (2008). Denying autonomy in order to create it: the paradox of forcing treatment upon addicts. Addiction, 103, 1919–1921.
Caplan, A. and Elliott, C. (2004). Is it ethical to use enhancement technologies to make us better than well?PLoS Medicine, 1, e52.
Cappella, J. N., Lerman, C., Romantan, A., et al. (2005). News about genetics and smoking. Communication Research, 32, 478.
Capps, B. (2007). Authoritative regulation and the stem cell debate. Bioethics Quarterly, 22, 43–55.
Capps, B., Campbell, A. V. and ter Meulen, R. (2008). Access to the UK Biobank Resource: Concepts of the Public Interest and the Public Good. London: Ethics and Governance Council of UK Biobank and the Wellcome Trust.
Carlsten, C. and Burke, W. (2006). Potential for genetics to promote public health: genetics research on smoking suggests caution about expectations. Journal of the American Medical Association, 296, 2480–2482.
Caron, L., Karkazis, K., Raffin, T. A., et al. (2005). Nicotine addiction through a neurogenomic prism: ethics, public health, and smoking. Nicotine & Tobacco Research, 7, 181–197.
Carpenter, M. J., Strange, C., Jones, Y., et al. (2007). Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Annals of Behavioral Medicine, 33, 22–28.
Carter, A., Ambermoon, P. and Hall, W. (2010a). Drug-induced impulse control disorders: a prospectus for neuroethical analysis. Neuroethics, DOI: 10.1007/s12152–010–9071–7.
Carter, A., Bell, E., Racine, E., et al. (2010b). Ethical issues raised by proposals to treat addiction using deep brain stimulation. Neuroethics, 1–14.
Carter, A., Capps, B. and Hall, W. (2009). Addiction Neurobiology: Ethical and Social Implications. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
Carter, A. and Hall, W. (2007a). The Ethical Use of Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization.
Carter, A. and Hall, W. (2007b). The social implications of neurobiological explanations of resistible compulsions. American Journal of Bioethics, 7, 15–17.
Carter, A. and Hall, W. (2008a). Informed consent to opioid agonist maintenance treatment: recommended ethical guidelines. International Journal of Drug Policy, 19, 79–89.
Carter, A. and Hall, W. (2008b). The issue of consent in research that administers drugs of addiction to addicted persons. Accountability in Research, 15, 209–225.
Carter, A. and Hall, W. (2011). Proposals to trial deep brain stimulation to treat addiction are premature. Addiction, 106, 235–237.
Casebeer, W. D. (2003). Natural Ethical Facts: Evolution, Connectionism, and Moral Cognition. Cambridge, MA: MIT Press.
Caspi, A. and Moffitt, T. E. (2006). Gene–environment interactions in psychiatry: joining forces with neuroscience. Nature Reviews. Neuroscience, 7, 583–590.
Cerny, E. H. and Cerny, T. (2008). Anti-nicotine abuse vaccines in the pipeline: an update. Expert Opinion on Investigational Drugs, 17, 691–696.
Chambers, R. A. (2008). Impulsivity, dual diagnosis, and the structure of motivated behavior in addiction. Behavioral and Brain Sciences, 31, 443–444.
Chandler, R. K., Fletcher, B. W. and Volkow, N. D. (2009). Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA, 301, 183–190.
Chapman, S. and MacKenzie, R. (2010). The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Medicine, 7, e1000216.
Charland, L. C. (2002). Cynthia's dilemma: consenting to heroin prescription. American Journal of Bioethics, 2, 37–47.
Chatterjee, A. (2004). Cosmetic neurology: the controversy over enhancing movement, mentation, and mood. Neurology, 63, 968–974.
Chatterjee, A. (2006). The promise and predicament of cosmetic neurology. Journal of Medical Ethics, 32, 110–113.
Chatterjee, A. (2007). Cosmetic neurology and cosmetic surgery: parallels, predictions, and challenges. Cambridge Quarterly of Healthcare Ethics, 16, 129–137.
Chavkin, W. (1996). Mandatory treatment for pregnant substance abusers: irrelevant and dangerous. Politics and the Life Sciences, 15, 53–54.
Chen, Y. C., Lu, R. B., Peng, G. S., et al. (1999). Alcohol metabolism and cardiovascular response in an alcoholic patient homozygous for the ALDH2*2 variant gene allele. Alcoholism, Clinical and Experimental Research, 23, 1853–1860.
Chervenak, F. A. and McCullough, L. B. (1997). Ethics in obstetrics and gynecology: an overview. European Journal of Obstetrics and Gynecology, 75, 91–94.
Childress, A. R., Mozley, P. D., McElgin, W., et al. (1999). Limbic activation during cue-induced cocaine craving. American Journal of Psychiatry, 156, 11–18.
Childress, J. F., Faden, R. R., Gaare, R. D., et al. (2002). Public health ethics: mapping the terrain. Journal of Law Medicine & Ethics, 30, 170–178.
Christensen, R., Kristensen, P. K., Bartels, E. M., et al. (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet, 370, 1706–1713.
Chuck, A., Jacobs, P., Logus, J. W., et al. (2005). Marginal cost of operating a positron emission tomography center in a regulatory environment. International Journal of Technology Assessment in Health Care, 21, 442–451.
Churchland, P. S. (1986). Neurophilosophy: Toward a Unified Science of the Mind-brain. Cambridge, MA.: MIT Press.
Clancey, G. and Howard, J. (2006). Diversion and criminal justice drug treatment: mechanism of emancipation or social control?Drug and Alcohol Review, 25, 377–385.
Cohen, J. (2004). HIV/AIDS in China. Changing course to break the HIV–heroin connection. Science, 304, 1434–1435.
Cohen, J. and Csete, J. (2006). As strong as the weakest pillar: harm reduction, law enforcement and human rights. International Journal of Drug Policy, 17, 101–103.
Cohen, J. E. and Amon, J. J. (2008). Health and human rights: concerns of drug users in detention in Guangxi Province, China. PLoS Medicine, 5, e234.
Cohen, P. J. (1997). Immunization for prevention and treatment of cocaine abuse: legal and ethical implications. Drug and Alcohol Dependence, 48, 167–174.
Cohen, P. J. (2002). Untreated addiction imposes an ethical bar to recruiting addicts for non-therapeutic studies of addictive drugs. Journal of Law, Medicine & Ethics, 30, 73–81.
Cohen, R. S. (1998). The Love Drug: Marching to the Beat of Ecstasy. New York: Haworth Medical Press.
Collins, D. and Lapsley, H. (2007). The Avoidable Costs of Alcohol Abuse in Australia and the Potential Benefits of Effective Policies to Reduce the Social Costs of Alcohol. Canberra: Department of Health and Ageing, Commonwealth of Australia.
Collins, D. and Lapsley, H. (2008). The Costs of Tobacco, Alcohol and Illicit Drug Use to Australian Society in 2004/05. National Drug Strategy Monograph No. 64. Canberra: Department of Health and Ageing, Commonwealth of Australia.
Collins, F. (1999). Medical and societal consequences of the Human Genome Project. New England Journal of Medicine, 341, 28–37.
Collins, F. (2003). A vision for the future of genomics research. Nature, 433, 835–847.
Comer, S. D., Sullivan, M. A., Yu, E., et al. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Archives of General Psychiatry, 63, 210–218.
Condit, C., Parrott, R. and Harris, T. (2006). Laypeople and behavioural genetics. In E. Parens, A. R. Chapman and N. Press (Eds.), Wrestling with Behavioral Genetics: Science, Ethics and Public Conversation (pp. 286–308). Baltimore, MD: Johns Hopkins University Press.
Conrad, P. (1992). Medicalization and social control. Annual Review of Sociology, 18, 209–232.
Contreras, M., Ceric, F. and Torrealba, F. (2007). Inactivation of the interoceptive insula disrupts drug craving and malaise induced by lithium. Science, 318, 655–658.
Cook, P. J. (2007). Paying the Tab: The Economics of Alcohol Policy. Princeton, NJ: Princeton University Press.
Cornuz, J., Zwahlen, S., Jungi, W. F., et al. (2008). A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE, 3, e2547.
Cosgrove, K. P. (2010). Imaging receptor changes in human drug abusers. In D.W. Self and J.K.Staley Gottschalk (Eds.), Behavioral Neuroscience of Drug Addiction (Vol. 3, pp. 199–217). Berlin: Springer.
Courtwright, D. T. (1982). Dark Paradise: Opiate Addiction in America Before 1940. Cambridge, MA: Harvard University Press.
Courtwright, D. T. (2001). Forces of Habit: Drugs and the Making of the Modern World. Cambridge, MA: Harvard University Press.
Cousins, M. S., Roberts, D. C. and de Wit, H. (2002). GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug and Alcohol Dependence, 65, 209–220.
Cox, W. M., Hogan, L. M., Kristian, M. R., et al. (2002). Alcohol attentional bias as a predictor of alcohol abusers' treatment outcome. Drug and Alcohol Dependence, 68, 237–243.
Craig, A. D. (2002). How do you feel? Interoception: the sense of the physiological condition of the body. Nature Reviews. Neuroscience, 3, 655–666.
Crick, F. (1995). The Astonishing Hypothesis: The Scientific Search for the Soul. New York: Simon & Schuster.
Cunningham, M. G., Bhattacharyya, S. and Benes, F. M. (2002). Amygdalo-cortical sprouting continues into early adulthood: implications for the development of normal and abnormal function during adolescence. Journal of Comparative Neurology, 453, 116–130.
Curran, H. V. (1991). Benzodiazepines, memory and mood: a review. Psychopharmacology, 105, 1–8.
Curran, H. V., Kleckham, J., Bearn, J., et al. (2001). Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. Psychopharmacology, 154, 153–160.
Dackis, C., Kampman, K., Lynch, K., et al. (2004). A double-blind, placebo-controlled trial of modafinil in cocaine dependence. Neuropsychopharmacology, 29, S72–S73.
Dackis, C. and O'Brien, C. (2005). Neurobiology of addiction: treatment and public policy ramifications. Nature Neuroscience, 8, 1431–1436.
Daglish, M. R., Weinstein, A., Malizia, A. L., et al. (2001). Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. American Journal of Psychiatry, 158, 1680–1686.
Daglish, M. R., Williams, T. M., Wilson, S., et al. (2008). Brain dopamine response in human opioid addiction. British Journal of Psychiatry, 193, 65–72.
Dalrymple, T. (2006). Romancing Opiates: Pharmacological Lies and the Addiction Bureaucracy. New York: Encounter Books.
Damasio, A. R. (1999). The Feeling of What Happens: Body and Emotion in the Making of Consciousness. New York: Harcourt Brace.
Damasio, A. R., Grabowski, T. J., Bechara, A., et al. (2000). Subcortical and cortical brain activity during the feeling of self-generated emotions. Nature Neuroscience, 3, 1049–1056.
Daniel, M., Martin, A. D. and Carter, J. (1992). Opiate receptor blockade by naltrexone and mood state after acute physical activity. British Journal of Sports Medicine, 26, 111–115.
Darke, S. and Hall, W. (2003). Heroin overdose: research and evidence-based intervention. Journal of Urban Health, 80, 189–200.
Darke, S. and Ross, J. (2002). Suicide among heroin users: rates, risk factors and methods. Addiction, 97, 1383–1394.
Darke, S. and Zador, D. (1996). Fatal heroin ‘overdose’: a review. Addiction, 91, 1765–1772.
Davies, J. B. (1997). The Myth of Addiction. Amsterdam: Harwood Academic.
De Quincey, T. (1900). Confessions of an Opium Eater. Literary Reminiscences. New York: D. Appleton.
Dean, A. J., Saunders, J. B., Jones, R. T., et al. (2006). Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. Journal of Psychiatry and Neuroscience, 31, 38–45.
Degenhardt, L., Bucello, C., Mathers, B., et al. (2011). Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction, 106, 32–51.
Demyttenaere, K., Bruffaerts, R., Posada-Villa, J., et al. (2004). Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. Journal of the American Medical Association, 291, 2581–2590.
Devlin, M. J. (2007). Is there a place for obesity in DSM-V?International Journal of Eating Disorders, 40 Suppl, S83–88.
Dewey, J. (1990). Logic: The Theory of Inquiry. Carbondale: Southern Illinois University Press.
Di Chiara, G. (1998). A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. Journal of Psychopharmacology, 12, 54–67.
Dieckmann, G. and Schneider, H. (1978). Influence of stereotactic hypothalamotomy on alcohol and drug addiction. Applied Neurophysiology, 41, 93–98.
Diefenbach, G. J., Diefenbach, D., Baumeister, A., et al. (1999). Portrayal of lobotomy in the popular press: 1935–1960. Journal for the History of the Neurosciences, 8, 60–69.
Dietrich, S., Matschinger, H. and Angermeyer, M. (2006). The relationship between biogenetic causal explanations and social distance toward people with mental disorders: results from a population survey in Germany. International Journal of Social Psychiatry, 52, 166–174.
Digiusto, E., Shakeshaft, A., Ritter, A., et al. (2004). Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction, 99, 450–460.
Dolan, K. (1999). The Epidemiology of Hepatitis C Infection in Prison Populations. Sydney: National Drug and Alcohol Research Centre, UNSW.
Dolan, K., Kite, B., Black, E., et al. (2006). HIV in prison in low-income and middle-income countries. The Lancet Infectious Diseases, 7, 32–41.
Dolan, K., Wodak, A., Hall, W., et al. (1996). HIV risk behaviour of injecting drug users before, during and after imprisonment in New South Wales. Addictive Research, 4, 151–160.
Dole, V. P. and Nyswander, M. (1965). A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. Journal of the American Medical Association, 193, 646.
Domes, G., Heinrichs, M., Glascher, J., et al. (2007a). Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biological Psychiatry, 62, 1187–1190.
Domes, G., Heinrichs, M., Michel, A., et al. (2007b). Oxytocin improves “mind-reading” in humans. Biological Psychiatry, 61, 731–733.
Donnelly, N., Hall, W. and Christie, P. (1995). The effects of partial decriminalisation on cannabis use in South Australia, 1985 to 1993. Australian Journal of Public Health, 19, 281–287.
Doran, C. M., Hall, W., Shakeshaft, A. P., et al. (2010). Alcohol policy reform in Australia: what can we learn from the evidence?The Medical Journal of Australia, 192, 468.
Doyle, C. (2004). DNA test can identify ‘the smoker's gene’. The Telegraph. Available at: http://www.telgraph.co.uk/news/main.jhtml?xml=/news/2004/12/02/nfag02.xml&sSheet=/news//12/02/ixhome.html (Accessed 25 January 2007.)
Drevets, W. C., Gautier, C., Price, J. C., et al. (2001). Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biological Psychiatry, 49, 81–96.
Dumit, J. (2004). Picturing Personhood: Brain Scans and Biomedical Identity. Princeton, NJ: Princeton University Press.
Dunn, L. B. and Jeste, D. V. (2001). Enhancing informed consent for research and treatment. Neuropsychopharmacology, 24, 595–607.
Dunn, L. B., Nowrangi, M. A., Palmer, B. W., et al. (2006). Assessing decisional capacity for clinical research or treatment: a review of instruments. American Journal of Psychiatry, 163, 1323–1334.
Dworkin, G. (1972). Paternalism. Monist, 56, 64–84.
Ebbets, J. (1994). Applicability of the CIWA-A scale. Clinical Institute Withdrawal Assessment for Alcohol. Journal of Nursing Care Quality, 8, ix–x.
Economic and Social Research Council. (2005). Research Ethics Framework (REF). Swindon, UK: Economic and Social Research Council.
Eigsti, I. M., Zayas, V., Mischel, W., et al. (2006). Predicting cognitive control from preschool to late adolescence and young adulthood. Psychological Science, 17, 478–484.
Elliott, C. (2002). Who holds the leash?American Journal of Bioethics, 2, 48.
Elliott, C. (2003). Better Than Well: American Medicine Meets the American Dream. New York: W.W. Norton.
Elliott, R., Csete, J., Wood, E., et al. (2005). Harm reduction, HIV/AIDS, and the human rights challenge to global drug control policy. Health and Human Rights, 8, 104–138.
Elster, J. and Skog, O. -J. (1999). Getting Hooked: Rationality and Addiction. Cambridge, UK: Cambridge University Press.
EMCDDA. (2006). Annual Report on the State of the Drugs Problem in the European Union, 2006. Belgium: European Monitoring Centre for Drugs and Drug Addiction.
Epstein, D. H., Preston, K. L., Stewart, J., et al. (2006). Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology, 189, 1–16.
Ersche, K., Fletcher, P. C., Lewis, S. J., et al. (2005). Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. Psychopharmacology, 180, 612–623.
Ersche, K., Roiser, J., Lucas, M., et al. (2011). Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology, 214, 779–789.
Eskapa, R. D. (2008). The Cure for Alcoholism: Drink Your Way Sober Without Willpower, Abstinence, or Discomfort. The Sinclair Method, a Medically Proven Cure for Alcoholism. Dallas, TX: BenBella Books.
Evans, J. P., Meslin, E. M., Marteau, T. M., et al. (2011). Deflating the genomic bubble. Science, 331, 861–862.
Everitt, B. J. and Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nature Neuroscience, 8, 1481–1489.
Ezzati, M., Lopez, A., Rogers, A., et al. (2004). Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization.
Faden, R. R., Beauchamp, T. L. and King, N. M. (1986). A History and Theory of Informed Consent. New York: Oxford University Press.
Faillace, L., Flamer, R., Imber, S., et al. (1972). Giving alcohol to alcoholics. Quarterly Journal of Studies on Alcohol, 33, 85–90.
Farabee, D. and Leukefeld, C. G. (2001). Recovery and the criminal justice system. In M. T. Frank, C. G. Leukefeld and J. J. Platt (Eds.), Relapse and Recovery in Addiction (pp. 40–59). London: Yale University Press.
Farah, M. J. (2002). Emerging ethical issues in neuroscience. Nature Neuroscience, 5, 1123–1129.
Farah, M. J. (2005). Neuroethics: the practical and the philosophical. Trends in Cognitive Sciences, 9, 34–40.
Farah, M. J. (2010). Neuroethics: An Introduction with Readings. Cambridge, MA: MIT Press.
Farah, M. J., Illes, J., Cook-Deegan, R., et al. (2004). Neurocognitive enhancement: what can we do and what should we do?Nature Reviews. Neuroscience, 5, 421–425.
Farah, M. J. and Wolpe, P. R. (2004). Monitoring and manipulating brain function: new neuroscience technologies and their ethical implications. Hastings Center Report, 34, 35–45.
FDA. (2009). FDA approves humanitarian device exemption for deep brain stimulator for severe obsessive-compulsive disorder. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149529.htm (Accessed 31 August, 2009.)
FDA. (2010). FDA approves injectable drug to treat opioid-dependent patients. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229109.htm (Accessed 12 October, 2010.)
Featherby, T., van den Buuse, M., Lubman, D. I., et al. (2008). Persistent downregulation of hippocampal CREB mRNA parallels a Y-maze deficit in adolescent rats following semi-chronic amphetamine administration. British Journal of Pharmacology, 154, 417–428.
Fehr, C., Yakushev, I., Hohmann, N., et al. (2008). Association of low striatal dopamine D2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. American Journal of Psychiatry, 165, 507–514.
Feil, J., Sheppard, D., Fitzgerald, P. B., et al. (2010). Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. Neuroscience & Biobehavioral Reviews, 35, 248–275.
Feinberg, J. (1971). Legal paternalism. Canadian Journal of Philosophy, 1, 105–124.
Feinberg, J. (1980). Rights, Justice, and the Bounds of Liberty: Essays in Social Philosophy. Princeton, N.J.: Princeton University Press.
Feltenstein, M. W. and See, R. E. (2008). The neurocircuitry of addiction: an overview. British Journal of Pharmacology, 154(2), 261–274.
Fenton, Z. (2003). Project Prevention: cash for birth control, a solution or a violation of rights. The Journal of Law in Society, 5, 199.
Festinger, D. S., Dugosh, K. L., Croft, J. R., et al. (2010). Corrected feedback: a procedure to enhance recall of informed consent to research among substance abusing offenders. Ethics & Behavior, 20, 387–399.
Festinger, D. S., Marlowe, D. B., Croft, J. R., et al. (2009). Monetary incentives improve recall of research consent information: it pays to remember. Experimental and Clinical Psychopharmacology, 17, 99–104.
Festinger, D. S., Ratanadilok, K., Marlowe, D. B., et al. (2007). Neuropsychological functioning and recall of research consent information among drug court clients. Ethics & Behavior, 17, 163–186.
Fillmore, M. T. (2003). Drug abuse as a problem of impaired control: current approaches and findings. Behavioural and Cognitive Neuroscience Reviews, 2, 179–197.
Fingarette, H. (1988). Heavy Drinking: The Myth of Alcoholism as a Disease. Berkley, CA: University of California Press.
Finnigan, F. and Hammerslay, R. (1992). The effect of alcohol on performance. In A. P. Smith and D. M. Jones (Eds.), Handbook of Human Performance, Health and Performance 2 (pp. 73–126). London: Academic Press.
Fiscella, K., Moore, A., Engerman, J., et al. (2005). Management of opiate detoxification in jails. Journal of Addictive Diseases, 24, 61–71.
Fisch, G. S. (2007). Animal models and human neuropsychiatric disorders. Behavior Genetics, V37, 1–10.
Fischer, H., Tillfors, M., Furmark, T., et al. (2001). Dispositional pessimism and amygdala activity: a PET study in healthy volunteers. Neuroreport, 12, 1635–1638.
Fischer, H., Wik, G. and Fredrikson, M. (1997). Extraversion, neuroticism and brain function: a PET study of personality. Personality and Individual Differences, 23, 345–352.
Fisher, C. B., Oransky, M., Mahadevan, M., et al. (2008). Marginalized populations and drug addiction research: realism, mistrust, and misconception. IRB; A Review of Human Subjects Research, 30, 1–9.
Fishman, M. (2008). Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction, 103, 1399–1401.
Fitzgerald, J. and Hamilton, M. (1996). The consequences of knowing: ethical and legal liabilities in illicit drug research. Social Science and Medicine, 43, 1591–1600.
Flowers, C. R. and Veenstra, D. (2004). The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics, 22, 481–493.
Foddy, B. and Savulescu, J. (2006). Addiction and autonomy: can addicted people consent to the prescription of their drug of addiction?Bioethics, 20, 1–15.
Foltz, E. L. and White, L. E., Jr. (1962). Pain “relief” by frontal cingulumotomy. Journal of Neurosurgery, 19, 89–100.
Forman, R. F., Bovasso, G., Woody, G., et al. (2002). Staff beliefs about drug abuse clinical trials. Journal of Substance Abuse Treatment, 23, 55–60.
Foster, K. R., Wolpe, P. R. and Caplan, A. L. (2003). Bioethics & the brain. IEEE Spectrum, 40, 34–39.
Fox, R. G. (1992). The compulsion of voluntary treatment in sentencing. Criminal Law Journal, 16, 37–54.
Frank, M. J., Samanta, J., Moustafa, A. A., et al. (2007). Hold your horses: impulsivity, deep brain stimulation, and medication in Parkinsonism. Science, 318, 1309–1312.
Franzini, A., Ferroli, P., Leone, M., et al. (2003). Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. Neurosurgery, 52, 1095–1099; discussion 1099–1101.
Franzini, A., Marras, C., Ferroli, P., et al. (2005). Stimulation of the posterior hypothalamus for medically intractable impulsive and violent behavior. Stereotactic and Functional Neurosurgery, 83, 63–66.
Fry, C. and Dwyer, R. (2001). For love or money? An exploratory study of why injecting drug users participate in research. Addiction, 96, 1319–1325.
Fry, C., Hall, W., Ritter, A., et al. (2006). The ethics of paying drug users who participate in research: a review and practical recommendations. Journal of Empirical Research on Human Research Ethics, 1, 21–36.
Fukuyama, F. (2002). Our Posthuman Future: Consequences of the Biotechnology Revolution. London: Profile Books.
Fureman, I., Meyers, K., McLellan, A. T., et al. (1997). Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV vaccine efficacy trials. AIDS Education and Prevention, 9, 330–341.
Gabriels, L., Cosyns, P., Nuttin, B., et al. (2003). Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatrica Scandinavica, 107, 275–282.
Gahlinger, P. M. (2004). Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. American Family Physician, 69, 2619–2626.
Gallinat, J., Bauer, M. and Heinz, A. (2008). Genes and neuroimaging: advances in psychiatric research. Neurodegenerative Disease, 5, 277–285.
Gao, G., Wang, X., He, S., et al. (2003). Clinical study for alleviating opiate drug psychological dependence by a method of ablating the nucleus accumbens with stereotactic surgery. Stereotactic and Functional Neurosurgery, 81, 96–104.
Garavan, H., Lingford-Hughes, A., Jones, T., et al. (2007). Neuroimaging. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 285–314). London: Academic Press.
Garavan, H. and Stout, J. C. (2005). Neurocognitive insights into substance abuse. Trends in Cognitive Sciences, 9, 195–201.
Garbutt, J. C., Kranzler, H. R., O'Malley, S. S., et al. (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA, 293, 1617–1625.
Gartner, C. E., Barendregt, J. J. and Hall, W. (2009). Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction, 104, 118–126.
Gartner, C. E., Hall, W., Vos, T., et al. (2007). Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet, 369, 2010–2014.
Gastfriend, D. R. (2011). Intramuscular extended-release naltrexone: current evidence. Annals of the New York Academy of Sciences, 1216, 144–166.
Geppert, C. M. A. and Roberts, L. W. (2005). Ethical issues in the use of genetic information in the workplace: a review of recent developments. Current Opinion in Psychiatry, 18, 518–524.
Gerstein, D. R. and Harwood, H. J. (1990). Treating Drug Problems (Volume 1). A Study of Effectiveness and Financing of Public and Private Drug Treatment Systems. Washington, DC: Institute of Medicine, National Academy Press.
Geyer, M. A. and Markou, A. (1995). Animal models of psychiatric disorders. In F. E. Bloom and D.J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 787–798). New York: Raven.
Gibson, A. E. and Degenhardt, L. J. (2007). Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug and Alcohol Review, 26, 405–410.
Gibson, A. E., Degenhardt, L. J. and Hall, W. (2007). Opioid overdose deaths can occur in patients with naltrexone implants. Medical Journal of Australia, 186, 152–153.
Gieringer, D. H. (2003). The acceptance of medicinal marijuana in the US. Journal of Cannabis Therapeutics, 3, 53–65.
Gillett, G. (2008). Subjectivity and Being Somebody: Human Identity and Neuroethics. Exeter, UK: Imprint Academic.
Gilmore, N. (1995). Drug use and human rights: privacy, vulnerability, disability and human rights infringements. Journal of Contemporary Health Law and Policy, 12, 355–447.
Giordano, J. and Gordijn, B. (2010). Scientific and Philosophical Perspectives in Neuroethics. New York: Cambridge University Press.
Gisquet, E. (2008). Cerebral implants and Parkinson's disease: a unique form of biographical disruption?Social Science and Medicine, 67, 1847–1851.
Glannon, W. (2006a). Bioethics and the Brain. New York: Oxford University Press.
Glannon, W. (2006b). Psychopharmacology and memory. Journal of Medical Ethics, 32, 74–78.
Glick, S. D., Maisonneuve, I. M., Kitchen, B. A., et al. (2002). Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. European Journal of Pharmacology, 438, 99–105.
Goff, P. (2005). ‘I was conscious as they pushed the needle deep into my brain’. The Telegraph. Available at: http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2005/11/20/wbrain20.xml (Accessed 6 July 2007.)
Gogtay, N., Giedd, J. N., Lusk, L., et al. (2004). Dynamic mapping of human cortical development during childhood through early adulthood. Proceedings of the National Academy of Sciences of the United States of America, 101, 8174–8179.
Gold, C. G., Cullen, D. J., Gonzales, S., et al. (1999). Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology, 91, 1639–1647.
Gold, L. H. and Koob, G. F. (1989). MDMA produces stimulant-like conditioned locomotor activity. Psychopharmacology, 99, 352–356.
Goldman, D., Oroszi, G. and Ducci, F. (2005). The genetics of addictions: uncovering the genes. Nature Reviews. Genetics, 6, 521–532.
Goldstein, A. and Herrera, J. (1995). Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug and Alcohol Dependence, 40, 139–150.
Goldstein, A. and Kalant, H. (1990). Drug policy: striking the right balance. Science, 249, 1513–1521.
Goldstein, R. Z., Alia-Klein, N., Tomasi, D., et al. (2007). Is decreased prefrontal cortical sensitivity to monetary reward associated with impaired motivation and self-control in cocaine addiction?American Journal of Psychiatry, 164, 43–51.
Goldstein, R. Z., Craig, A. D., Bechara, A., et al. (2009). The neurocircuitry of impaired insight in drug addiction. Trends in Cognitive Sciences, 13, 372–380.
Goldstein, R. Z. and Volkow, N. D. (2002). Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. American Journal of Psychiatry, 159, 1642–1652.
Gonzalez, G., Oliveto, A. and Kosten, T. R. (2004). Combating opiate dependence: a comparison among the available pharmacological options. Expert Opinion on Pharmacotherapy, 5, 713–725.
Goodman, A. (2008). Neurobiology of addiction: an integrative review. Biochemical Pharmacology, 75, 266–322.
Gorelick, D., Pickens, R. W. and Benkovsky, F. O. (1999). Clinical research in substance abuse: human subjects issues. In H. A. Pinchus, J. A. Lieberman and S. Ferris (Eds.), Ethics in Psychiatric Research: A Resource Manual for Human Subjects' Protection (pp. 177–194). Washington, DC: American Psychiatric Association.
Gostin, L. O. (1993). Compulsory treatment for drug-dependent persons: justifications for a public health approach to drug dependency. In R. Bayer and G. M. Oppenheimer (Eds.), Confronting Drug Policy: Illicit Drugs in a Free Society (pp. 561–593). Cambridge, UK: Cambridge University Press.
Gostin, L. O. (2001). Beyond moral claims: a human rights approach in mental health. Cambridge Quarterly of Healthcare Ethics, 10, 264–274.
Gostin, L. O. and Mann, J. M. (1999). Toward a development of a human rights impact assessment for the formulation and evaluation of public health policies. In J. M. Mann (Ed.), Health and Human Rights: A Reader (pp. 54–72). London: Routledge.
Goudriaan, A., Grekin, E. R. and Sher, K. J. (2008a). The predictive value of neurocognitive decision-making for heavy alcohol use in a longitudinal, prospective study. European Neuropsychopharmacology, 18, S69–S70.
Goudriaan, A., Oosterlaan, J., De Beurs, E., et al. (2008b). The role of self-reported impulsivity and reward sensitivity versus neurocognitive measures of disinhibition and decision-making in the prediction of relapse in pathological gamblers. Psychological Medicine, 38, 41–50.
Gowing, L., Ali, R. and White, J. (2006). Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database of Systematic Reviews, CD002022.
Gowing, L., Ali, R. and White, J. M. (2009). Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, CD002025.
Granfield, R. and Cloud, W. (1996). The elephant that no one sees: natural recovery among middle-class addicts. Journal of Drug Issues, 26, 45–61.
Grant, J. E., Brewer, J. A. and Potenza, M. N. (2006). The neurobiology of substance and behavioral addictions. CNS Spectrums, 11, 924.
Grant, J. E., Odlaug, B. L., Potenza, M. N., et al. (2010). Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. British Journal of Psychiatry, 197, 330–331.
Grant, S., Contoreggi, C. and London, E. D. (2000). Drug abusers show impaired performance in a laboratory test of decision making. Neuropsychologia, 38, 1180–1187.
Greely, H. (2001). Genotype discrimination: the complex case for some legislative protection. University of Pennsylvania Law Review, 149, 1438–1505.
Greely, H., Sahakian, B., Harris, J., et al. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456, 702–705.
Greenberg, B. D., Malone, D. A., Friehs, G. M., et al. (2006). Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology, 31, 2384–2393.
Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 376, 595–605.
Grisso, T. and Applebaum, P. S. (1998). Assessing Competence to Consent to Treatment: A Guide for Physicians and Other Health Professionals. New York: Oxford University Press.
Guichard, A., Lert, F., Brodeur, J. M., et al. (2007). Buprenorphine substitution treatment in France: drug users' views of the doctor–user relationship. Social Science & Medicine, 64, 2578–2593.
Gundle, K. R., Dingel, M. J. and Koenig, B. A. (2010). ‘To prove this is the industry's best hope’: big tobacco's support of research on the genetics of nicotine addiction. Addiction, 105, 974–983.
Haga, S. B., Khoury, M. J. and Burke, W. (2003). Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nature Genetics, 34, 347–350.
Hall, L. L. (1996). The human implications of psychiatric genetics. In L. L. Hall (Ed.), Genetics and Mental Illness: Evolving Issues for Research and Society (pp. 157–188). New York, NY: Plenum Press.
Hall, M. A. and Rich, S. S. (2000). Laws restricting health insurers' use of genetic information: impact on genetic discrimination. American Journal of Human Genetics, 66, 293–307.
Hall, W. (1997a). The recent Australian debate about the prohibition on cannabis use. Addiction, 92, 1109–1116.
Hall, W. (1997b). The role of legal coercion in the treatment of offenders with alcohol and heroin problems. Australian and New Zealand Journal of Criminology, 30, 103–120.
Hall, W. (2000). UROD: an antipodean therapeutic enthusiasm. Addiction, 95, 1765–1766.
Hall, W. (2002a). The prospects for immunotherapy in smoking cessation. Lancet, 360, 1089–1091.
Hall, W. (2002b). Taking Darwin seriously: more than telling “just so” stories. Addiction, 97, 472–473.
Hall, W. (2004). Feeling ‘better than well’: can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods?EMBO Reports, 5, 1105–1109.
Hall, W. (2005a). British drinking: a suitable case for treatment?British Medical Journal, 331, 527–528.
Hall, W. (2005b). Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases?PLoS Medicine, 2, e266; quiz e351.
Hall, W. (2006a). The regulatory challenges in engineering a safer tipple. Journal of Psychopharmacology, 20, 321–322.
Hall, W. (2006b). Stereotactic neurosurgical treatment of addiction: minimising the chances of another ‘great and desperate cure’. Addiction, 101, 1–3.
Hall, W. (2007). A research agenda for assessing the potential contribution of genomic medicine to tobacco control. Tobacco Control, 16, 53–58.
Hall, W. (2008). The contribution of research to the development of a national cannabis policy in Australia. Addiction, 103, 712–720.
Hall, W., Capps, B. and Carter, A. (2008). The use of depot naltrexone under legal coercion: the case for caution. Addiction, 103, 1922–1924.
Hall, W. and Carter, L. (2004). Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence. Journal of Medical Ethics, 30, 337–340.
Hall, W., Carter, L. and Morley, K. I. (2004a). Neuroscience research on the addictions: a prospectus for future ethical and policy analysis. Addictive Behaviors, 29, 1481–1495.
Hall, W. and Degenhardt, L. (2009). Adverse health effects of non-medical cannabis use. Lancet, 374, 1383–1391.
Hall, W., Doran, C., Degenhardt, L., et al. (2006). Illicit opiate use. In D. T. Jamison (Ed.), Disease Control Priorities in Developing Countries (pp. 907–931). New York: Oxford University Press.
Hall, W., Gartner, C. E. and Carter, A. (2008). The genetics of nicotine addiction liability: ethical and social policy implications. Addiction, 103, 350–359.
Hall, W. and Lucke, J. (2010a). The enhancement use of neuropharmaceuticals: more scepticism and caution needed. Addiction, 105, 2041–2043.
Hall, W. and Lucke, J. (2010b). Legally coerced treatment for drug using offenders: ethical and policy issues. Crime and Justice Bulletin, 144, 1–12.
Hall, W., Madden, P. and Lynskey, M. (2002). The genetics of tobacco use: methods, findings and policy implications. Tobacco Control, 11, 119–124.
Hall, W. and Mattick, R. P. (2000). Is ultra-rapid opioid detoxification a viable option in the treatment of opioid dependence?CNS Drugs, 14, 251–255.
Hall, W., Morley, K. I. and Lucke, J. (2004b). The prediction of disease risk in genomic medicine: scientific prospects and implications for public policy and ethics. EMBO Reports, 5, S22–S26.
Hall, W. and Pacula, R. L. (2003). Cannabis Use and Dependence: Public Health and Public Policy. Cambridge: Cambridge University Press.
Hall, W., Room, R. and Bondy, S. (1999). Comparing the health and psychological risks of alcohol, cannabis, nicotine and opiate use. In H. Kalant, W. Corrigal, W. Hall, et al. (Eds.), The Health Effects of Cannabis (pp. 475–506). Toronto: Centre for Addiction and Mental Health.
Hall, W. and Sannibale, C. (1996). Are there two types of alcoholism?Lancet, 348, 1258.
Hamani, C., McAndrews, M. P., Cohn, M., et al. (2008). Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Annals of Neurology, 63, 119–123.
Hamilton, R. J., Olmedo, R. E., Shah, S., et al. (2002). Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Academic Emergency Medicine, 9, 63–68.
Hando, J. and Darke, S. (1998). NSW Drug Trends 1997. Findings from the Illicit Drug Reporting System (IDRS). National Drug and Alcohol Research Centre Technical Report 56. Sydney: National Drug and Alcohol Research Centre, University of New South Wales.
Harrison, K., Vlahov, D., Jones, K., et al. (1995). Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 10, 386–390.
Harwood, H. J. and Myers, T. G. (2004). New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington, DC: National Academies Press.
Hasin, D. S. (1994). Treatment/self-help for alcohol-related problems: relationship to social pressure and alcohol dependence. Journal of Studies on Alcohol, 55, 660–666.
Hasman, A. and Holm, S. (2004). Nicotine conjugate vaccine: is there a right to a smoking future?Journal of Medical Ethics, 30, 344–345.
Hauser, M. D. (2006). Moral Minds: How Nature Designed our Universal Sense of Right and Wrong. New York: Ecco.
Hawkins, J. D., Catalano, R. F. and Miller, J. Y. (1992). Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychological Bulletin, 112, 64–105.
Hazelton, L. D., Sterns, G. L. and Chisholm, T. (2003). Decision-making capacity and alcohol abuse: clinical and ethical considerations in personal care choices. General Hospital Psychiatry, 25, 130–135.
Healy, D. (2002). The Creation of Psychopharmacology. Cambridge, MA: Harvard University Press.
Healy, D. (2004). Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. New York: New York University Press.
Heinz, A., Reimold, M., Wrase, J., et al. (2005). Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Archives of General Psychiatry, 62, 57–64.
Heinze, H. J., Heldmann, M., Voges, J., et al. (2009). Counteracting incentive sensitization in severe alcohol dependence using deep brain stimulation of the nucleus accumbens: clinical and basic science aspects. Frontiers in Human Neuroscience, 3, 22.
Heinzerling, K. G., Swanson, A.-N., Kim, S., et al. (2010). Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 109, 20–29.
Hejazi, N. S. (2007). Pharmacogenetic aspects of addictive behaviors. Dialogues in Clinical Neuroscience, 9, 447–454.
Helfand, W. H. (1996). Selling addiction cures. Transactions and Studies of the College of Physicians of Philadelphia, 18, 85–108.
Herz, A. (1997). Endogenous opioid systems and alcohol addiction. Psychopharmacology, 129, 99–111.
Hester, R. and Garavan, H. (2004). Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. Journal of Neuroscience, 24, 11017–11022.
Heyman, G. (2009). Addiction: A Disorder of Choice. Cambridge, MA: Harvard University Press.
Higgins, S. T. (2006). Extending contingency management to the treatment of methamphetamine use disorders. American Journal of Psychiatry, 163, 1870–1872.
Higgins, S. T., Delaney, D. D., Budney, A. J., et al. (1991). A behavioral approach to achieving initial cocaine abstinence. American Journal of Psychiatry, 148, 1218–1224.
Higgins, S. T. and Petry, N. M. (1999). Contingency management. Incentives for sobriety. Alcohol Research and Health, 23, 122–127.
Hill, E. M. and Newlin, D. B. (2002). Evolutionary approaches to addiction: introduction. Addiction, 97, 375–379.
Ho, M. K., Goldman, D., Heinz, A., et al. (2010). Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clinical Pharmacology and Therapeutics, 88, 779–791.
Hoff, N., Evers-Casey, S., Weibel, S., et al. (2005). Impact of genetic risk information on smokers' motivation to quit. RP-062, S16. 11th Annual Meeting of the Society for Research on Nicotine and Tobacco. Prague, Czech Republic.
Holden, C. (2001). ‘Behavioral’addictions: do they exist?Science, 294, 980–982.
Holtzman, N. A. and Marteau, T. M. (2000). Will genetics revolutionize medicine?New England Journal of Medicine, 343, 141–144.
Horka-Ruiz, J. (2000). Preventing the birth of drug-addicted babies through contract: an examination of the CRACK Organization. William and Mary Journal of Women and the Law, 7, 473.
Hotopf, M. (2005). The assessment of mental capacity. Clinical Medicine, 5, 580–584.
Hotze, T. D., Shah, K., Anderson, E. E., et al. (2011). “Doctor, would you prescribe a pill to help me. . .?” A national survey of physicians on using medicine for human enhancement. The American Journal of Bioethics, 11, 3–13.
Hubbard, R. L., Collins, J. J., Rachal, J. H., et al. (1988). The criminal justice client in drug abuse treatment. In C. Leukefeld and F. M. Tims (Eds.), Compulsory Treatment of Drug Abuse: Research and Clinical Practice. Rockville, MD: National Institute of Drug Abuse.
Hughes, J. R. (2009). Smokers' beliefs about the inability to stop smoking. Addictive Behaviors, 34, 1005–1009.
Hulse, G. K., Arnold-Reed, D. E., O'Neil, G., et al. (2004). Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addiction Biology, 9, 67–72.
Hulse, G. K., English, D. R., Milne, E., et al. (1999). The quantification of mortality resulting from the regular use of illicit opiates. Addiction, 94, 221–229.
Hulse, G. K., Stalenberg, V., McCallum, D., et al. (2005). Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans. Journal of Controlled Release, 108, 43–55.
Hume, D. (1978). A Treatise of Human Nature. Oxford: Oxford University Press.
Husak, D. N. (1992). Drugs and Rights. Cambridge, England: Cambridge University Press.
Hutcheson, D. M., Everitt, B. J., Robbins, T. W., et al. (2001). The role of withdrawal in heroin addiction: enhances reward or promotes avoidance?Nature Neuroscience, 4, 943–947.
Hutchison, K. E. (2010). Substance use disorders: realizing the promise of pharmacogenomics and personalized medicine. Annual Review of Clinical Psychology, 6, 577–589.
Huxley, A. (1954). The Doors of Perception. New York: Harper.
Hyman, S. E. (2005). Addiction: a disease of learning and memory. American Journal of Psychiatry, 162, 1414–1422.
Hyman, S. E. (2007). The neurobiology of addiction: implications for voluntary control of behavior. American Journal of Bioethics, 7, 8–11.
Hyman, S. E., Malenka, R. C. and Nestler, E. J. (2006). Neural mechanisms of addiction: the role of reward-related learning and memory. Annual Review of Neuroscience, 29, 565–598.
Illes, J. (2003). Neuroethics in a new era of neuroimaging. American Journal of Neuroradiology, 24, 1739–1741.
Illes, J. (2006). Neuroethics: Defining the Issues in Theory, Practice, and Policy. Oxford: Oxford University Press.
Illes, J. (2007). Empirical neuroethics. Can brain imaging visualize human thought? Why is neuroethics interested in such a possibility?EMBO Reports, 8 Spec No, S57–60.
Illes, J., Kirschen, M. P., Edwards, E., et al. (2006). Ethics. Incidental findings in brain imaging research. Science, 311, 783–784.
Illes, J., Kirschen, M. P., Karetsky, K., et al. (2004a). Discovery and disclosure of incidental findings in neuroimaging research. Journal of Magnetic Resonance Imaging, 20, 743–747.
Illes, J. and Racine, E. (2005). Imaging or imagining? A neuroethics challenge informed by genetics. American Journal of Bioethics, 5, 5–18.
Illes, J., Rosen, A., Greicius, M., et al. (2007). Prospects for prediction: ethics analysis of neuroimaging in Alzheimer's disease. Annals of the New York Academy of Sciences, 1097, 278–295.
Illes, J., Rosen, A. C., Huang, L., et al. (2004b). Ethical consideration of incidental findings on adult brain MRI in research. Neurology, 62, 888–890.
Insel, T. R. (2009). Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Archives of General Psychiatry, 66, 128–133.
International Federation of Red Cross and Red Crescent Societies and Francois-Xavier Bagnoud Center for Health and Human Rights. (1999). Human rights: an introduction. In J. M. Mann (Ed.), Health and Human Rights: A Reader (pp. 21–28). London: Routledge.
Ioannidis, J. P. (2011). Excess significance bias in the literature on brain volume abnormalities. Archives of General Psychiatry, 10.1001/archgenpsychiatry.2011.28.
Ito, H., Matsuo, K., Wakai, K., et al. (2006). An intervention study of smoking cessation with feedback on genetic cancer susceptibility in Japan. Preventive Medicine, 42, 102–108.
Iversen, L. (2002). The Science of Marijuana. Oxford: Oxford University Press.
Iversen, S. and Iversen, L. (2007). Dopamine: 50 years in perspective. Trends in Neurosciences, 30, 188–193.
Iverson, L., Morris, K. and Nutt, D. (2007). Pharmacology and treatments. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 169–208). London: Academic Press.
Jayaram-Lindstrom, N., Hammarberg, A., Beck, O., et al. (2008). Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. American Journal of Psychiatry, 165, 1442–1448.
Jentsch, J. D. and Taylor, J. R. (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology, 146, 373–390.
Jeste, D. V. and Saks, E. (2006). Decisional capacity in mental illness and substance use disorders: empirical database and policy implications. Behavioral Sciences and the Law, 24, 607–628.
John, U., Meyer, C., Hapke, U., et al. (2004). Nicotine dependence, quit attempts, and quitting among smokers in a regional population sample from a country with a high prevalence of tobacco smoking. Preventive Medicine, 38, 350–358.
Johnson, B. A., Rosenthal, N., Capece, J. A., et al. (2007). Topiramate for treating alcohol dependence: a randomized controlled trial. Journal of the American Medical Association, 298, 1641–1651.
Joint Committee of the American Bar Association and the American Medical Association on Narcotic Drugs. (1961). Drug Addiction: Crime or Disease. Bloomington: Indiana University Press.
Joly, Y., Braker, M. and Le Huynh, M. (2010). Genetic discrimination in private insurance: global perspectives. New Genetics and Society, 29, 351–368.
Jonsen, A. R. (1998). The Birth of Bioethics. New York: Oxford University Press.
Jorenby, D. E., Leischow, S. J., Nides, M. A., et al. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine, 340, 685–691.
Jupp, B. and Lawrence, A. J. (2009). New horizons for therapeutics in drug and alcohol abuse. Pharmacology and Therapeutics, 125(1), 138–168.
Jurgens, R. and Betteridge, G. (2005). Prisoners who inject drugs: public health and human rights imperatives. Health and Human Rights, 8, 46–74.
Kagan, J. (2006). An Argument for Mind. London: Yale University Press.
Kalant, H. (2010). What neurobiology cannot tell us about addiction. Addiction, 105, 780–789.
Kalivas, P. W. and Volkow, N. D. (2005). The neural basis of addiction: a pathology of motivation and choice. American Journal of Psychiatry, 162, 1403–1413.
Kampman, K. M., Pettinati, H., Lynch, K. G., et al. (2004). A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence, 75, 233–240.
Kampman, K. M., Volpicelli, J. R., Mulvaney, F., et al. (2001). Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug and Alcohol Dependence, 63, 69–78.
Kanaka, T. S. and Balasubramaniam, V. (1978). Stereotactic cingulumotomy for drug addiction. Applied Neurophysiology, 41, 86–92.
Kandel, E. (2006). In Search of Memory: The Emergence of a New Science of Mind. New York: W.W. Norton.
Kant, I. (1996). The Metaphysics of Morals. New York: Cambridge University Press.
Kantak, K. M. (2003). Vaccines against drugs of abuse: a viable treatment option?Drugs, 63, 341–352.
Karila, L., Weinstein, A., Aubin, H. -J., et al. (2010). Pharmacological approaches to methamphetamine dependence: a focused review. British Journal of Clinical Pharmacology, 69, 578–592.
Kariminia, A., Law, M. G., Butler, T. G., et al. (2007). Suicide risk among recently released prisoners in New South Wales, Australia. Medical Journal of Australia, 187, 387–390.
Kass, L. (2002). Life, Liberty and the Defense of Dignity. San Francisco, CA: Encounter Books.
Kauer, J. and Malenka, R. C. (2007). Synaptic plasticity and addiction. Nature Reviews. Neuroscience, 8, 844–858.
Keane, H. (2005). Moral frameworks, ethical engagement and harm reduction: commentary on “Ethical challenges and responses in harm reduction research: promoting applied communitarian ethics” by C. L. Fry, C. Treloar and L. Maher. Drug and Alcohol Review, 24, 551–552.
Kelley, A. E. (2004). Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron, 44, 161–179.
Kelley, A. E. and Berridge, K. C. (2002). The neuroscience of natural rewards: relevance to addictive drugs. Journal of Neuroscience, 22, 3306–3311.
Kelman, H. (1964). Narcotic Withdrawal Syndrome. Suppression of by means of electric convulsive therapy. Minnesota Medicine, 47, 525–527.
Kenney, C., Simpson, R., Hunter, C., et al. (2007). Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. Journal of Neurosurgery, 106, 621–625.
Kessler, R. C., Berglund, P. M., Demler, O. M., et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593–602.
Khantzian, E. J. (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry, 142, 1259–1264.
Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Review of Psychiatry, 4, 231–244.
Khoury, M. J., McCabe, L. L. and McCabe, E. R. B. (2003). Genomic medicine: population screening in the age of genomic medicine. New England Journal of Medicine, 348, 50–58.
Khoury, M. J., Thrasher, J. F., Burke, W., et al. (2000). Challenges in communicating genetics: a public health approach. Genetics in Medicine, 2, 198–202.
Khoury, M. J., Yang, Q. H., Gwinn, M., et al. (2004). An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genetics in Medicine, 6, 38–47.
Kilts, C. D., Schweitzer, J. B., Quinn, C. K., et al. (2001). Neural activity related to drug craving in cocaine addiction. Archives of General Psychiatry, 58, 334–341.
Kiluk, B. D., Nich, C. and Carroll, K. M. (2010). Neurocognitive indicators predict results of an informed-consent quiz among substance-dependent treatment seekers entering a randomized clinical trial. Journal of Studies on Alcohol and Drugs, 71, 704–712.
Kirchmayer, U., Davoli, M. and Verster, A. (2003). Naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews, 2, CD001333.
Kirulis, K. and Zacny, J. (1998). Do healthy volunteers increase drug usage after participation in research involving opioids and nitrous oxide?Anesthesiology, 89, 1222.
Kisely, S. (2008). The case for policy reform in cannabis control. Canadian Journal of Psychiatry, 53, 795–797.
Klag, S., O'Callaghan, F. and Creed, P. (2005). The use of legal coercion in the treatment of substance abusers: an overview and critical analysis of thirty years of research. Substance Use & Misuse, 40, 1777–1795.
Kleber, H. D. and Riordan, C. E. (1982). The treatment of narcotic withdrawal: a historical review. Journal of Clinical Psychiatry, 43, 30–34.
Kleiman, M. (1992). Against Excess: Towards a Drug Policy that Works. New York: Basic Books.
Kleinig, J. (1985). Ethical Issues in Psychosurgery. London: Allen & Unwin.
Kleinig, J. (2004). Ethical issues in substance use intervention. Substance Use & Misuse, 39, 369–398.
Klingemann, H. and Bergmark, A. (2006). The legitimacy of addiction treatment in a world of smart people. Addiction, 101, 1230–1237.
Knapp, C. M., Tozier, L., Pak, A., et al. (2009). Deep brain stimulation of the nucleus accumbens reduces ethanol consumption in rats. Pharmacology, Biochemistry & Behavior, 92, 474–479.
Knight, G. (1969). Chronic depression and drug addiction treated by stereotactic surgery. Nursing Times, 65, 583–586.
Knightly, P. (1979). Suffer the Children: The Story of Thalidomide. New York: The Viking Press.
Kolb, L. and Himmelsbach, C. K. (1938). Clinical studies of drug addiction III: a critical review of the withdrawal treatments with method of evaluating abstinence syndromes. American Journal of Psychiatry, 94, 759–799.
Koob, G. F. (1999). Stress, corticotropin-releasing factor, and drug addiction. Annals of the New York Academy of Sciences, 897, 27–45.
Koob, G. F. (2008). A role for brain stress systems in addiction. Neuron, 59, 11–34.
Koob, G. F. and Bloom, F. E. (1988). Cellular and molecular mechanisms of drug dependence. Science, 242, 715–723.
Koob, G. F. and Kreek, M. J. (2007). Stress, dysregulation of drug reward pathways, and the transition to drug dependence. American Journal of Psychiatry, 164, 1149–1159.
Koob, G. F. and Le Moal, M. (1997). Drug abuse: hedonic homeostatic dysregulation. Science, 278, 52–58.
Koob, G. F. and Le Moal, M. (2005). Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nature Neuroscience, 8, 1442–1444.
Koob, G. F. and Le Moal, M. (2006). Neurobiology of Addiction. New York: Academic Press.
Koob, G. F. and Le Moal, M. (2008). Addiction and the brain antireward system. Annual Review of Psychology, 59, 29–53.
Koob, G. F., Lloyd, G. K. and Mason, B. J. (2009). Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nature Reviews Drug Discovery, 8, 500–515.
Korf, D. J. (2002). Dutch coffee shops and trends in cannabis use. Addictive Behaviors, 27, 851–866.
Kosfeld, M., Heinrichs, M., Zak, P. J., et al. (2005). Oxytocin increases trust in humans. Nature, 435, 673–676.
Kosten, T. and Owens, S. M. (2005). Immunotherapy for the treatment of drug abuse. Pharmacology & Therapeutics, 108, 76–85.
Kosten, T., Rosen, M., Bond, J., et al. (2002). Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine, 20, 1196–1204.
Krack, P., Hariz, M. I., Baunez, C., et al. (2010). Deep brain stimulation: from neurology to psychiatry?Trends in Neurosciences, 33, 474–484.
Kranzler, H. R., Dolinsky, Z. and Kaplan, R. F. (1990). Giving ethanol to alcoholics in a research setting: its effect on compliance with disulfiram treatment. British Journal of Addiction, 85, 119–123.
Kranzler, H. R., Modesto-Lowe, V. and Nuwayser, E. S. (1998). Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcoholism, Clinical and Experimental Research, 22, 1074–1079.
Krupitsky, E. and Blokhina, E. A. (2010). Long-acting depot formulations of naltrexone for heroin dependence: a review. Current Opinion in Psychiatry, 23(3), 210–214.
Krupitsky, E., Zvartau, E., Masalov, D. V., et al. (2004). Naltrexone for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 26, 285–294.
Krupitsky, E., Zvartau, E. and Woody, G. (2010). Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Current Psychiatry Reports, 12, 448–453.
Kruptisky, E. M., Burakov, A. M., Tsoy, M. V., et al. (2007). Overcoming opioid blockade from depot naltrexone (Prodetoxon®). Addiction, 102, 1164–1165.
Kuehn, B. M. (2009). Studies linking smoking-cessation drug with suicide risk spark concerns. JAMA, 301, 1007–1008.
Kuhn, J., Bauer, R., Pohl, S., et al. (2009). Observations on unaided smoking cessation after deep brain stimulation of the nucleus accumbens. European Addiction Research, 15, 196–201.
Kuhn, J., Lenartz, D., Huff, W., et al. (2007). Remission of alcohol dependency following deep brain stimulation of the nucleus accumbens: valuable therapeutic implications?Journal of Neurology, Neurosurgery and Psychiatry, 78, 1152–1153.
Kunoe, N., Lobmaier, P., Vederhus, J. K., et al. (2009). Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. British Journal of Psychiatry, 194, 541–546.
Lahti, T., Halme, J. T., Pankakoski, M., et al. (2010). Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacology Bulletin, 43, 35–44.
Lanteri, C., Salomon, L., Torrens, Y., et al. (2008). Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism. Neuropsychopharmacology, 33, 1724–1734.
LaRowe, S. D., Mardikian, P., Malcolm, R., et al. (2006). Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. The American Journal of Addictions, 15, 105–110.
Larriviere, D., Williams, M. A., Rizzo, M., et al. (2009). Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. Neurology, 73, 1406–1412.
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., et al. (1995). SPECT imaging of striatal dopamine release after amphetamine challenge. Journal of Nuclear Medicine, 36, 1182–1190.
Lawford, B. R., Young, R. M., Noble, E. P., et al. (2000). The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. American Journal of Medical Genetics, 96, 592–598.
Leader, A. E., Lerman, C. and Cappella, J. N. (2010). Nicotine vaccines: will smokers take a shot at quitting?Nicotine and Tobacco Research, 12, 390–397.
Lee, A. M. and Tyndale, R. F. (2006). Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. Journal of Psychopharmacology, 20, 7–14.
Lerman, C. and Berrettini, W. (2003). Elucidating the role of genetic factors in smoking behavior and nicotine dependence. American Journal of Medical Genetics, 118, 48–54.
Lerman, C., Gold, K., Audrain, J., et al. (1997). Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking related cognitions, emotions and behavior change. Health Psychology, 16, 87–99.
Leshner, A. I. (1997). Addiction is a brain disease, and it matters. Science, 278, 45–47.
Leshner, A. I. (2005). It's time to go public with neuroethics. American Journal of Bioethics, 5, 1–2.
Leukefeld, C. G. and Tims, F. M. (1988). Compulsory Treatment of Drug Abuse: Research and Clinical Practice. Rockville, MD: National Institute on Drug Abuse.
Levin, F. R., Evans, S. M., Brooks, D. J., et al. (2007). Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence, 87, 20–29.
Levy, D., Shabat-Simon, M., Shalev, U., et al. (2007). Repeated electrical stimulation of reward-related brain regions affects cocaine but not “natural” reinforcement. Journal of Neuroscience, 27, 14179–14189.
Levy, N. (2006a). Addiction, autonomy and ego-depletion: a response to Bennett Foddy and Julian Savulescu. Bioethics, 20, 16–20.
Levy, N. (2006b). Autonomy and addiction. Canadian Journal of Philosophy, 36, 427–448.
Levy, N. (2007). Neuroethics: Challenges for the 21st Century. Cambridge: Cambridge University Press.
Levy, N. and Clarke, S. (2008). Neuroethics and psychiatry. Current Opinion in Psychiatry, 21, 568–571.
Li, M. D. and Burmeister, M. (2009). New insights into the genetics of addiction. Nature Reviews. Genetics, 10, 225–231.
Lim, S. Y., O'Sullivan, S. S., Kotschet, K., et al. (2009). Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. Journal of Clinical Neuroscience, 16, 1148–1152.
Ling, W., Casadonte, P., Bigelow, G., et al. (2010). Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA, 304, 1576–1583.
Ling, W. and Compton, P. (2005). Recent advances in the treatment of opiate addiction. Clinical Neuroscience Research, 5, 161–167.
Lingford-Hughes, A. and Nutt, D. (2003). Neurobiology of addiction and implications for treatment. British Journal of Psychiatry, 182, 97–100.
Lingford-Hughes, A., Welch, S. and Nutt, D. (2004). Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 18, 293–335.
Lipsman, N., Neimat, J. S. and Lozano, A. M. (2007). Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery, 61, 1–11; discussion 11–13.
Liu, H. Y., Jin, J., Tang, J. S., et al. (2008). Chronic deep brain stimulation in the rat nucleus accumbens and its effect on morphine reinforcement. Addiction Biology, 13, 40–46.
Loimer, N., Schmid, R., Lenz, K., et al. (1990). Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. British Journal of Psychiatry, 157, 748–752.
Loimer, N., Schmid, R., Presslich, O., et al. (1988). Naloxone treatment for opiate withdrawal syndrome. British Journal of Psychiatry, 153, 851–852.
Lu, L., Wang, X. and Kosten, T. R. (2009). Stereotactic neurosurgical treatment of drug addiction. American Journal of Drug and Alcohol Abuse, 35, 391–393.
Lubman, D., Hides, L., Yücel, M., et al. (2007a). Intervening early to reduce developmentally harmful substance use among youth populations. Medical Journal of Australia, 187, S22–25.
Lubman, D., Yucel, M. and Hall, W. (2007b). Substance use and the adolescent brain: a toxic combination?Journal of Psychopharmacology, 21, 792–794.
Lucke, J., Bell, S., Partridge, B., et al. (2011a). Academic doping or Viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals. EMBO Reports, 12, 197–201.
Lucke, J., Bell, S., Partridge, B., et al. (2011b). Deflating the neuroenhancement bubble. American Journal of Bioethics – Neuroscience, in press.
Lucke, J., Diedrichs, P. C., Partridge, B., et al. (2009). Anticipating the anti-ageing pill. Lessons from the history of the oral contraceptive pill and hormone replacement therapy. EMBO Reports, 10, 108–113.
Lynskey, M. and Hall, W. (2001). Attention Deficit Hyperactivity Disorder and substance use disorders: is there a causal link?Addiction, 96, 815–822.
Lysaught, M. T. (2004). Respect: or, how respect for persons became respect for autonomy. Journal of Medicine and Philosophy, 29, 665–680.
Lyvers, M. and Yakimoff, M. (2003). Neuropsychological correlates of opioid dependence and withdrawal. Addictive Behaviors, 28, 605–611.
Maastricht University Medical Center. (2009). A phase 2B, multi-center, randomized, double-blinded, parallel-arm study to assess efficacy and safety of 3'′-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) as an aid in smoking cessation. Available at: http://clinicaltrials.gov/ct2/show/NCT00995033 (Accessed 6 October 2010.)
MacCoun, R. (2004). Anticipating unintended consequences of vaccine-like immunotherapies and depot medications of addictive drug use. In H. J. Harwood and T. G. Myers (Eds.), New Treatments for Addiction: Behavioral, Ethical, Legal and Social Questions (pp. 241–275). Washington, DC: National Academies Press.
MacCoun, R. and Reuter, P. (1997). Interpreting Dutch cannabis policy: reasoning by analogy in the legalization debate. Science, 278, 47.
MacCoun, R. and Reuter, P. (2001). Drug-war Heresies: Learning from Other Vices, Times and Places. Cambridge: Cambridge University Press.
Machii, K., Cohen, D., Ramos-Estebanez, C., et al. (2006). Safety of rTMS to non-motor cortical areas in healthy participants and patients. Clinical Neurophysiology, 117, 455–471.
MacIntyre, A. (1985). After Virtue: A Study in Moral Theory. London: Duckwirth.
MacIntyre, A. (1998). A Short History of Ethics: A History of Moral Philosophy from the Homeric Age to the Twentieth Century. Notre Dame, IN: University of Notre Dame Press.
Madden, R. G. (1996). Civil commitment for substance abuse by pregnant women? A view from the front lines. Politics and the Life Sciences, 15, 56–59.
Maddux, J. (1988). Clinical experience with civil commitment. In C. G. Leukefeld and F. M. Tims (Eds.), Compulsory Treatment of Drug Abuse: Research and Clinical Experience (Vol. 86, pp. 35–56). Rockville, MD: National Institute on Drug Addiction.
Maher, B. (2008). Poll results: look who's doping. Nature, 452, 674–675.
Maldonado, R. (1997). Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neuroscience and Biobehavioral Reviews, 21, 91–104.
Mann, J. M. (1997). Medicine and public health, ethics and human rights. Hastings Center Report, 27, 6–13.
Mann, J. M. (1999). Health and human rights. In J. M. Mann (Ed.), Health and Human Rights: A Reader (pp. 7–20). London: Routledge.
Mantione, M., van de Brink, W., Schuurman, P. R., et al. (2010). Smoking cessation and weight loss after chronic deep brain stimulation of the nucleus accumbens: therapeutic and research implications: case report. Neurosurgery, 66, E218; discussion E218.
Marcus, S. (Ed.). (2002). Neuroethics: Mapping the Field. Conference Proceedings (13–14 May, 2002). San Fransisco: The Dana Foundation.
Mardikian, P. N., LaRowe, S. D., Hedden, S., et al. (2007). An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 389–394.
Marinelli, M. and Piazza, P. V. (2002). Interaction between glucocorticoid hormones, stress and psychostimulant drugs. European Journal of Neuroscience, 16, 387–394.
Marlowe, D. B. (2006). Depot naltrexone in lieu of incarceration: a behavioral analysis of coerced treatment for addicted offenders. Journal of Substance Abuse Treatment, 31, 131–139.
Marteau, T., Ashcroft, R. E. and Oliver, A. (2009). Using financial incentives to achieve healthy behaviour. British Medical Journal, 338, 983–985.
Marteau, T. and Lerman, C. (2001). Genetic risk and behavioural change. British Medical Journal, 322, 1056–1059.
Marteau, T., Munafò, M. R., Aveyard, P., et al. (2010). Trial protocol: using genotype to tailor prescribing of nicotine replacement therapy. A randomised controlled trial assessing impact of communication upon adherence. BMC Public Health, 10, 680.
Marteau, T. and Richards, D. (1996). The Troubled Helix: Social and Psychological Implications of the New Human Genetics. New York: Cambridge University Press.
Marteau, T. and Weinman, J. (2006). Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Social Science and Medicine, 62, 1360–1368.
Martell, B. A., Orson, F. M., Poling, J., et al. (2009). Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Archives of General Psychiatry, 66, 1116–1123.
Mathieu, D. (1995). Mandating treatment for pregnant substance abusers: a compromise. Politics and the Life Sciences, 14, 199–208.
Matthew-Simmons, F., Love, S. and Ritter, A. (2008). A Review of Australian Public Opinion Surveys on Illicit Drugs. Sydney: National Drug and Alcohol Research Centre, University of New South Wales.
Mattick, R. P., Breen, C., Kimber, J., et al. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, 3, CD002209.
Mattick, R. P. and Hall, W. (1996). Are detoxification programmes effective?Lancet, 347, 97–100.
Mattick, R. P., Kimber, J., Breen, C., et al. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2, CD002207.
Mayberg, H. S., Lozano, A. M., Voon, V., et al. (2005). Deep brain stimulation for treatment-resistant depression. Neuron, 45, 651–660.
Mayor, S. (1997). Specialists criticise treatment for heroin addiction. British Medical Journal, 314, 1365.
Maze, I. and Nestler, E. J. (2011). The epigenetic landscape of addiction. Annals of the New York Academy of Sciences, 1216, 99–113.
McAllister, W. B. (2000). Drug Diplomacy in the Twentieth Century: An International History. London: Routledge.
McBride, C. M., Bepler, G., Lipkus, I. M., et al. (2002). Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiology, Biomarkers and Prevention, 11, 521–528.
McBride, C. M., Bowen, D., Brody, L. C., et al. (2010). Future health applications of genomics: priorities for communication, behavioral, and social sciences research. American Journal of Preventive Medicine, 38, 556–565.
McCabe, D. P. and Castel, A. D. (2008). Seeing is believing: the effect of brain images on judgments of scientific reasoning. Cognition, 107, 343–352.
McClure, S. M., Daw, N. D. and Montague, P. R. (2003). A computational substrate for incentive salience. Trends in Neurosciences, 26, 423–428.
McCrady, B. S. and Bux, D. A., Jr. (1999). Ethical issues in informed consent with substance abusers. Journal of Consulting and Clinical Psychology, 67, 186–193.
McGee, G. (1999). Pragmatic methods and bioethics. In G. McGee (Ed.), Pragmatic Bioethics (pp. 18–29). London: Vanderbilt University Press.
McGregor, I. S., Callaghan, P. D. and Hunt, G. E. (2008). From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?British Journal of Pharmacology, 154, 358–368.
McKeganey, N., Neale, J., Lloyd, C., et al. (2007). Sociology and substance use. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 359–388). London: Academic Press.
McLellan, A. T., Lewis, D. C., O'Brien, C. P., et al. (2000). Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA, 284, 1689–1695.
McLellan, A. T., Skipper, G. S., Campbell, M., et al. (2008). Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. British Medical Journal, 337, a2038.
McNeely, H. E., Mayberg, H. S., Lozano, A. M., et al. (2008). Neuropsychological impact of Cg25 deep brain stimulation for treatment-resistant depression: preliminary results over 12 months. Journal of Nervous and Mental Disease, 196, 405–410.
Medvedev, S. V., Anichkov, A. D. and Poltakov Iu, I. (2003). Physiological mechanisms of the effectiveness of bilateral stereotactic cingulotomy in treatment of strong psychological dependence in drug addiction. Fiziologiia Cheloveka, 29, 117–123.
Mehta, M. A., Owen, A. M., Sahakian, B. J., et al. (2000). Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. Journal of Neuroscience, 20, RC65.
Merikangas, K. R., Mehta, R. L., Molnar, B. E., et al. (1998). Comorbidity of substance use disorders with mood and anxiety disorders: results of the international consortium in psychiatric epidemiology. Addictive Behaviors, 23, 893–907.
Merikangas, K. R. and Risch, N. (2003). Genomic priorities and public health. Science, 302, 599–601.
Merrick, J. C. (1996). Pregnancy and substance abuse: education or mandatory treatment?Politics and the Life Sciences, 15, 59–60.
Midanik, L. (2006). Biomedicalization of Alcohol Studies: Methodological Shifts and Institutional Challenges. New Brunswick, NJ: Transaction Publishers.
Milekic, M. H., Brown, S. D., Castellini, C., et al. (2006). Persistent disruption of an established morphine conditioned place preference. Journal of Neuroscience, 26, 3010–3020.
Mill, J. S. (2001). Utilitarianism. Indianapolis: Hackett.
Milton, A. L., Lee, J. L. and Everitt, B. J. (2008). Reconsolidation of appetitive memories for both natural and drug reinforcement is dependent on {beta}-adrenergic receptors. Learning and Memory, 15, 88–92.
Minogue, K. and Marshall, E. (2010). Guatemala study from 1940s reflects a ‘dark chapter’ in medicine. Science, 330, 160.
Mintzer, M. Z., Copersino, M. L. and Stitzer, M. L. (2005). Opioid abuse and cognitive performance. Drug and Alcohol Dependence, 78, 225–230.
Mintzer, M. Z. and Stitzer, M. L. (2002). Cognitive impairment in methadone maintenance patients. Drug and Alcohol Dependence, 67, 41–51.
Miotto, K., McCann, M., Basch, J., et al. (2002). Naltrexone and dysphoria: fact or myth?American Journal on Addictions, 11, 151–160.
Modell, J. G., Glaser, F. B. and Mountz, J. M. (1993). The ethics and safety of alcohol administration in the experimental setting to individuals who have chronic, severe alcohol problems. Alcohol and Alcoholism, 28, 189–197.
Montoya, I. D. and Haertzen, C. (1994). Reduction of psychopathology among individuals participating in non-treatment drug abuse residential studies. Journal of Addictive Disorders, 13, 89–97.
Montreal Gazette. (2006). Who rules the medicine cabinet? Montreal Gazette. Available at: http://www.canada.com/montrealgazette/story.html?id=65bee20c-b7b9-46ca-87c7-7477cec32bdb&k=89866.
Moore, D., Aveyard, P., Connock, M., et al. (2009). Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. British Medical Journal, 338, b1024.
Moreno, A. Y., Azar, M. R.,